What's Happening?
Bracco, a leader in diagnostic imaging, has expressed strong support for the American Society of Nuclear Cardiology's (ASNC) recent position statement. The ASNC recommends cardiac positron emission tomography (PET) with myocardial blood flow (MBF) quantification
as the preferred method for evaluating coronary artery disease (CAD). This endorsement is based on clinical evidence suggesting that cardiac PET is superior to SPECT imaging in detecting heart disease, assessing patient risk, and diagnosing complex cases. Bracco has been a proponent of this approach since 1989, working to lower barriers to entry and increase access to cardiac PET imaging. The company offers Cardiogen-82, a rubidium Rb 82 generator for myocardial perfusion imaging, and HeartSee, a platform for generating coronary flow capacity maps.
Why It's Important?
The ASNC's endorsement of cardiac PET imaging is significant for the medical community and patients with coronary artery disease. Cardiac PET's ability to provide more accurate diagnoses and better risk assessments can lead to improved patient outcomes. This development may influence healthcare providers to adopt cardiac PET more widely, potentially leading to changes in diagnostic practices and healthcare policies. Bracco's long-standing advocacy and investment in this technology highlight its commitment to advancing cardiovascular imaging, which could drive further innovation and adoption in the field.
